Zacks Investment Research·5 days ago
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis DeviceAORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Artivion, Inc.(AORT)Earnings, Financials & Key Ratios
AORT•NYSE
$24.66
117.4× P/E·Price updated Jul 6, 2026
AboutArtivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.Show more
- Revenue$441M+13.6%
- EBITDA$49M-22.0%
- Net Income$10M+173.1%
- EPS (Diluted)0.21+165.6%
- Gross Margin61.28%-4.3%
- EBITDA Margin11.15%-31.3%
- Operating Margin6.06%-39.4%
- Net Margin2.21%+164.4%
- ROE2.7%+156.3%
AORT Price & Volume
Artivion, Inc. (AORT) stock price & volume — 10-year historical chart
Loading chart...
Strategic Pivot Drives Revenue Growth Amid Volatility
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Regulatory approval timeline delays
Key Thesis Takeaways
- Artivion is successfully executing a strategic transition toward high-tech aortic solutions, evidenced by a 17.5% year-over-year revenue growth in 2026Q1.
- While the company has significantly improved its capital structure by reducing its debt-to-equity ratio from 1.23 in 2025Q1 to 0.57 in 2026Q1, investors should remain cautious regarding persistent operating margin compression, which has largely remained in the low single digits.
- Future performance hinges on the company's ability to scale its proprietary device portfolio while managing the inherent working capital volatility of its consignment-based sales model.
Verdict Logic
while the company has successfully reduced its debt-to-equity ratio to 0.57, the current forward P/E of 248.53 appears to price in significant future growth that may be challenged by ongoing operating margin volatility.
AORT Growth Metrics
Artivion, Inc. (AORT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.7%
5 Years11.75%
3 Years12.04%
TTM17.59%
Profit CAGR
10 Years9.33%
5 Years-
3 Years-
TTM154.63%
EPS CAGR
10 Years4.14%
5 Years-
3 Years-
TTM146.72%
Return on Capital
10 Years2.85%
5 Years2.33%
3 Years3.23%
Last Year3.55%
AORT Recent Earnings
Artivion, Inc. (AORT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.08+33.3%
$0.06
Rev
$116M+0.6%
$116M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.17+21.4%
$0.14
Rev
$116M-0.4%
$116M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.16+14.3%
$0.14
Rev
$113M-2.6%
$116M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.24+118.2%
$0.11
Rev
$113M+5.1%
$107M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.08vs $0.06+33.3% | $116Mvs $116M+0.6% |
| Q1 2026 | Feb 12, 2026 | $0.17vs $0.14+21.4% | $116Mvs $116M-0.4% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.14+14.3% | $113Mvs $116M-2.6% |
| Q3 2025 | Aug 7, 2025 | $0.24vs $0.11+118.2% | $113Mvs $107M+5.1% |
Based on last 12 quarters of dataView full earnings history →
Latest AORT News
Recent stock market news and headlines for Artivion, Inc. (AORT)
Seeking Alpha·6 days ago
Artivion: PMA Approval Supports Accelerating Growth And Margin ExpansionArtivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major adverse events, with the elimination of DANE tears and durable benefit, supporting rapid, adoption-driven commercial scaling. AORT demonstrates double-digit revenue growth, margin expansion, and a shift to GAAP profitability, with EBITDA up 26% and gross margins nearing 65%.
PRNewsWire·Jun 29, 2026
Artivion Announces U.S. FDA Approval of the AMDS Hybrid ProsthesisATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections.
Peers Comparison
Key metrics vs top competitors for Artivion, Inc. (AORT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.66 | $1.2B | 117.43 | 13.59% | 2.21% | 2.7% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $32.39 | $1.64B | -134.96 | 14.88% | -0.83% | -0.95% | — | |
| $1.32 | $91.87M | -1.14 | 15.4% | -523.83% | -51.88% | — | |
| $71.23 | $2.46B | 14.63 | 37.13% | 27.04% | 41.92% | — | |
| $179.95 | $9.42B | -64.27 | -27.1% | 4.9% | 9.08% | — |
Compare AORT vs Peers
Artivion, Inc. (AORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AORT SEC Filings & Documents
Artivion, Inc. (AORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
May 7, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when AORT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AORT Frequently Asked Questions
Artivion, Inc. (AORT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Artivion, Inc.'s revenue?
Artivion, Inc. (AORT) reported $458.7M in revenue for fiscal year 2025. This represents a 1140% increase from $37.0M in 1996.
How fast is Artivion, Inc. growing?
Artivion, Inc. (AORT) grew revenue by 13.6% over the past year. This is steady growth.
Is AORT profitable?
Yes, Artivion, Inc. (AORT) is profitable, generating $11.7M in net income for fiscal year 2025 (2.2% net margin).
Dividend & Returns
What is AORT's return on equity?
Artivion, Inc. (AORT) has a return on equity (ROE) of 2.7%. This is below average, suggesting room for improvement.
What is Artivion, Inc.'s free cash flow?
Artivion, Inc. (AORT) generated $12.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.